Transcatheter Aortic Valve Replacement in Pure Aortic Regurgitation: The Randomized SEASON-AR Clinical Trial
Source: View publication →
In patients with severe pure aortic regurgitation at high surgical risk, transfemoral TAVR combined with guideline-directed medical therapy significantly reduced the 1-year composite rate of death, disabling stroke, or heart failure rehospitalization compared with medical therapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SEASON-AR trial is the first adequately powered randomized clinical trial to demonstrate that TAVR plus GDMT is markedly superior to GDMT alone for patients with severe pure aortic regurgitation who are unsuitable for surgery, filling a major evidence gap where previous clinical guidelines remained cautious.
Historical Context
While TAVR has become an established and revolutionary treatment for severe aortic stenosis, its application in pure aortic regurgitation (AR) has been limited by technical challenges, such as the absence of annular calcification for device anchoring and larger aortic root dimensions. Historically, patients with pure AR at prohibitive surgical risk had only guideline-directed medical therapy available, which offered limited efficacy in altering the natural history of the disease. Prior to SEASON-AR, evidence supporting TAVR in pure AR relied predominantly on observational registries and off-label device usage.
Guided Discussion
High-yield insights from every perspective
Why has transcatheter aortic valve replacement historically been contraindicated or considered highly challenging for patients with pure severe aortic regurgitation compared to those with severe aortic stenosis?
Key Response
Pure aortic regurgitation typically lacks the heavy annular and leaflet calcification seen in aortic stenosis. This calcification is crucial for the anchoring and sealing of standard transcatheter heart valves. Without it, there is a significantly higher risk of valve migration, device embolization, and severe paravalvular leak.
A 78-year-old patient with severe pure aortic regurgitation and an STS score of 9% (high surgical risk) is evaluated for intervention. Based on the SEASON-AR trial, how does TAVR compare to medical therapy, and what medical therapy components are considered guideline-directed for chronic severe AR?
Key Response
The SEASON-AR trial demonstrated that TAVR combined with GDMT significantly reduces the 1-year composite rate of death, disabling stroke, or HF rehospitalization compared to GDMT alone in high-risk patients. GDMT for severe AR typically focuses on controlling hypertension with ACE inhibitors or ARBs and managing heart failure symptoms if present, though vasodilators do not delay the need for surgery in asymptomatic patients with normal LV function.
What specific transcatheter valve design features and procedural imaging techniques are required to overcome the anatomical challenges of pure aortic regurgitation, and how do rates of pacemaker implantation and paravalvular leak in this population compare to TAVR for calcific aortic stenosis?
Key Response
Intervening on pure AR often requires devices with specific anchoring mechanisms (e.g., clipping onto leaflets) or relies heavily on significant valve oversizing and precise 3D transesophageal echocardiography and CT sizing, as fluoroscopic calcific landmarks are absent. Off-label use of standard valves in pure AR has historically been associated with higher rates of significant paravalvular leak and need for permanent pacemakers or valve-in-valve procedures compared to calcific AS.
How should the results of the SEASON-AR trial shift our heart team discussions for patients with pure severe AR who are deemed prohibitive or high-risk for surgical valve replacement, and what are the limitations of a 1-year follow-up for this specific cohort?
Key Response
Historically, high-risk AR patients were relegated to palliative medical therapy with poor prognoses. SEASON-AR establishes TAVR as a viable, life-extending option for this cohort, shifting the heart team consensus from comfort care to transcatheter intervention. However, a 1-year follow-up is insufficient to assess long-term valve durability and the delayed consequences of trace-to-mild paravalvular leak, which are critical in the context of progressive ventricular remodeling in AR.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In evaluating a composite primary endpoint of death, disabling stroke, or heart failure rehospitalization in an unblinded device-versus-medical-therapy trial like SEASON-AR, what statistical and methodological biases might inflate the treatment effect, and how can time-to-first-event analyses be improved?
Key Response
In unblinded trials, soft endpoints like heart failure rehospitalization are highly susceptible to ascertainment and admission bias, as clinicians may be less likely to admit a patient who recently received a novel device. Using hierarchical methods like the win ratio or joint frailty models accounts for the severity of events (prioritizing death over HF hospitalization), preventing the overall composite from being disproportionately driven by the least severe, most subjective component.
If you were peer-reviewing the SEASON-AR manuscript, what specific anatomical exclusion criteria and baseline echocardiographic parameters would you scrutinize to determine if the study population is truly representative of the general pure AR population rather than a highly selected subset?
Key Response
A rigorous reviewer would flag whether patients with extreme annular dilation, significant aortopathies, or bicuspid valves were excluded, as these are common in pure AR and notoriously difficult for TAVR. If the trial only included patients with perfectly sized annuli and normal ascending aortas, the external validity is severely compromised, necessitating transparent reporting of screening logs and anatomical screen-failure rates.
Current ACC/AHA guidelines strongly recommend surgical AVR for symptomatic severe AR but provide limited options for high-surgical-risk patients. How might the SEASON-AR data alter the next iteration of valvular heart disease guidelines regarding the Class of Recommendation and Level of Evidence for TAVR in pure AR?
Key Response
Currently, TAVR for pure AR is not widely endorsed in guidelines due to a lack of randomized data, often receiving a Class 2b or no recommendation for prohibitive risk patients. With SEASON-AR demonstrating superiority over GDMT in a randomized fashion, the committee would likely consider adding a Class 2a (Level of Evidence B-R) recommendation for TAVR in symptomatic patients with severe pure AR who are at high or prohibitive surgical risk, provided their anatomy is suitable.
Clinical Landscape
Noteworthy Related Trials
PARTNER 3 Trial
Tested
Balloon-expandable TAVR
Population
Patients with severe aortic stenosis at low surgical risk
Comparator
Surgical Aortic Valve Replacement (SAVR)
Endpoint
Composite of death, stroke, or rehospitalization at 1 year
Evolut Low Risk Trial
Tested
Self-expanding TAVR
Population
Patients with severe aortic stenosis at low surgical risk
Comparator
Surgical Aortic Valve Replacement (SAVR)
Endpoint
Composite of all-cause mortality or disabling stroke at 24 months
ALIGN-AR Trial
Tested
JenaValve Trilogy TAVR system
Population
High-risk patients with symptomatic severe pure aortic regurgitation
Comparator
Pre-specified performance goals (Single-arm trial)
Endpoint
All-cause mortality at 1 year
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis